Mesoblast (MEOBF) Goodwill & Intangibles (2015 - 2026)
Mesoblast's (MEOBF) quarterly Goodwill & Intangibles came in at $566.4 million in Q2 2026, down 0.95% year-over-year from $571.8 million in Q2 2025, and little changed quarter-over-quarter from $568.8 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Goodwill & Intangibles (2015 - 2026) Analysis & Trends
Mesoblast has disclosed Goodwill & Intangibles across 12 years of filings, most recently posting $566.4 million for Q2 2026.
- In Q2 2026, Goodwill & Intangibles fell 0.95% year-over-year to $566.4 million; the TTM figure through Jun 2026 stood at $566.4 million (down 0.95% YoY), while the FY2026 annual figure was $566.4 million, down 0.95% from the prior year.
- Goodwill & Intangibles came in at $566.4 million for Q2 2026 at Mesoblast, roughly flat from $568.8 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $578.9 million in Q1 2022 to a low of $566.4 million in Q2 2026.
- Average Goodwill & Intangibles over 5 years is $575.2 million, with a median of $576.9 million recorded in 2023.
- Year-over-year, Goodwill & Intangibles decreased 0.23% in 2023 and slipped 1.06% in 2025.
- Over 5 years, Goodwill & Intangibles stood at $577.9 million in 2022, then retreated by 0.23% to $576.6 million in 2023, then fell by 0.29% to $574.9 million in 2024, then dropped by 1.06% to $568.8 million in 2025, then slipped by 0.43% to $566.4 million in 2026.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $566.4 million in Q2 2026, $568.8 million in Q4 2025, and $571.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 566.37 Mn |
| Dec 31, 2025 | 568.80 Mn |
| Jun 30, 2025 | 571.83 Mn |
| Dec 31, 2024 | 574.88 Mn |
| Jun 30, 2024 | 575.74 Mn |
| Dec 31, 2023 | 576.56 Mn |
| Jun 30, 2023 | 577.18 Mn |
| Mar 31, 2023 | 577.53 Mn |
| Dec 31, 2022 | 577.90 Mn |
| Sep 30, 2022 | 578.28 Mn |
| Jun 30, 2022 | 578.65 Mn |
| Mar 31, 2022 | 578.95 Mn |
| Dec 31, 2021 | 579.84 Mn |
| Sep 30, 2021 | 580.18 Mn |
| Jun 30, 2021 | 580.55 Mn |
| Mar 31, 2021 | 580.94 Mn |
| Dec 31, 2020 | 581.33 Mn |
| Sep 30, 2020 | 581.22 Mn |
| Jun 30, 2020 | 581.60 Mn |
| Mar 31, 2020 | 581.94 Mn |